449 related articles for article (PubMed ID: 22894670)
1. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.
Kaumaya PT; Foy KC
Future Oncol; 2012 Aug; 8(8):961-87. PubMed ID: 22894670
[TBL] [Abstract][Full Text] [Related]
2. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine.
Kaumaya PT
Future Oncol; 2020 Aug; 16(23):1767-1791. PubMed ID: 32564612
[TBL] [Abstract][Full Text] [Related]
3. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
4. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.
Kaumaya PT
Hum Vaccin Immunother; 2015; 11(6):1368-86. PubMed ID: 25874884
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH
Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045
[TBL] [Abstract][Full Text] [Related]
6. Cell signalling: growth factors and tyrosine kinase receptors.
Perona R
Clin Transl Oncol; 2006 Feb; 8(2):77-82. PubMed ID: 16632420
[TBL] [Abstract][Full Text] [Related]
7. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics.
Miller MJ; Foy KC; Kaumaya PT
Discov Med; 2013 Mar; 15(82):166-76. PubMed ID: 23545045
[TBL] [Abstract][Full Text] [Related]
9. VEGF/VEGFR signalling as a target for inhibiting angiogenesis.
Kiselyov A; Balakin KV; Tkachenko SE
Expert Opin Investig Drugs; 2007 Jan; 16(1):83-107. PubMed ID: 17155856
[TBL] [Abstract][Full Text] [Related]
10. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
Front Immunol; 2020; 11():895. PubMed ID: 32528470
[TBL] [Abstract][Full Text] [Related]
11. Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors.
de Aguiar RB; de Moraes JZ
Front Immunol; 2019; 10():1023. PubMed ID: 31156623
[TBL] [Abstract][Full Text] [Related]
12. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.
Sharma PS; Sharma R; Tyagi T
Curr Cancer Drug Targets; 2011 Jun; 11(5):624-53. PubMed ID: 21486218
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
Schenone S; Bondavalli F; Botta M
Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
Tie J; Desai J
Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
[TBL] [Abstract][Full Text] [Related]
15. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
Foy KC; Wygle RM; Miller MJ; Overholser JP; Bekaii-Saab T; Kaumaya PT
J Immunol; 2013 Jul; 191(1):217-27. PubMed ID: 23698748
[TBL] [Abstract][Full Text] [Related]
16. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors.
Bekaii-Saab T; Wesolowski R; Ahn DH; Wu C; Mortazavi A; Lustberg M; Ramaswamy B; Fowler J; Wei L; Overholser J; Kaumaya PTP
Clin Cancer Res; 2019 Jun; 25(12):3495-3507. PubMed ID: 30804020
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of cancer in 2012.
Kirkwood JM; Butterfield LH; Tarhini AA; Zarour H; Kalinski P; Ferrone S
CA Cancer J Clin; 2012; 62(5):309-35. PubMed ID: 22576456
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
Féliz LR; Tsimberidou AM
Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of tumor by targeting angiogenesis.
Hou J; Tian L; Wei Y
Sci China C Life Sci; 2004 Dec; 47(6):545-52. PubMed ID: 15620111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
